Influence of concurrent and sequential combination of postoperative radiation and endocrine therapy (aromatase inhibitor or tamoxifen) on radiation-induced lung injury
10.3760/cma.j.issn.1006-9801.2009.11.003
- VernacularTitle:乳腺癌术后辅助放疗联合芳香化酶抑制剂或他莫昔芬对放射性肺损伤的影响
- Author:
Chengbo HAN
;
Fan LI
;
Jietao MA
;
Wei JING
;
Jianzhu ZHAO
;
Huawei ZOU
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Radiotherapy;
Endocrine therapy;
Radiation-induced lung injury
- From:
Cancer Research and Clinic
2009;21(11):728-730
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare radiation-induced lung injury (RILI) between concurrent and sequential combination of postoperative radiotherapy and endocrine therapy. Methods A total of 118 patients subjected by radical or modified radical operation of breast cancer were enrolled in this study and received radiotherapy and endocrine therapy between Jan 2003 and December 2007. All the patients were categorized into four groups: radiotherapy (RT) plus concurrent aromatase inhibitor(AI): RT+AI; RT plus sequential AI:RT-AI; RT plus tamoxifen (TAM): RT+TAM; RT plus sequential TAM: RT-TAM. Radiotherapy was delivered by using various energy of electron (6, 9, 12 Mev β-ray) or 6 M.V X-ray for different target with a dose of 50 Gy (2 Gy/Fx, 5 fractions per week). RILI grades were classified according to RTOG/EORTC and Aoki evaluation criteria from one month to at least one year after radiotherapy. Results 30/118(25.4 %) patients was observed with RILI, RT+AI 22.7 % vs. RT-AI 20.0 %(P =0.806), RT+TAM 35.7 % vs. RT-TAM 24.2 %(P =0.328). The incident rate of RILI was higher in elder patients(>60 yr) than in other patients (33.9 % vs.16.9 %, P =0.05). Patients with positive chemotherapy history had a higher risk of RILI than those with chemotherapy-negtive history (P =0.039). Conclusion These findings suggest that RILI are associated with age and chemotherapy history, but not correlated with the sequence of radiotherapy and endocrine therapy.
